Trinity Biotech Secures $2.5M Loan, Waives Covenants, and Amends Convertible Note with Highly Dilutive Terms
TRIB sits 27% above its 52-week low of $0.501 on light trading volume (0.2× avg).
Summary
Trinity Biotech amended its credit agreement with Perceptive, securing a $2.5 million term loan and a waiver for covenant non-compliance, while also increasing convertible debt and significantly lowering the conversion price, signaling severe financial distress.
Key Events · Financing and Capital Events · TRIB
-
Covenant Waiver Granted
Lender Perceptive Credit Holdings III, LP provided a limited waiver for Trinity Biotech's non-compliance with certain financial covenants, indicating the company violated its debt terms.
-
New Term Loan Secured
Trinity Biotech received an additional $2.5 million term loan from Perceptive Credit Holdings III, LP, providing a critical, albeit costly, capital infusion.
-
Convertible Note Amended
The aggregate convertible indebtedness increased by $12.5 million to $72.5 million, and the minimum conversion price was significantly reduced from $1.03 to $0.5061 per ADS.
-
High Potential Dilution
The amended terms, particularly the drastically reduced conversion price, indicate substantial potential future dilution for existing shareholders, as the new conversion price is below the current stock price.
Analysis · TRIB · Life Sciences
This Schedule 13D/A provides critical details on how Trinity Biotech is addressing the severe financial pressure and "going concern" doubts disclosed in its 20-F filing on the same day. The company secured a $2.5 million term loan and a waiver for non-compliance with financial covenants from its lender, Perceptive. However, these measures come at a significant cost: the convertible note's aggregate amount increased by $12.5 million, and its conversion price was drastically reduced from $1.03 to $0.5061 per ADS. This indicates a highly dilutive financing arrangement, reflecting the company's desperate need for capital and the lender's strong position. The total new/increased financing ($15 million) significantly exceeds the company's current market capitalization, underscoring the severity of its financial situation and the potential for substantial future dilution.
At the time of this filing, TRIB was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.50 to $3.44. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.